Logo

NMPA- China Accepts NDA for BeiGene & Boehringer BioChina's Tislelizumab for the treatment of r/r cHL

Share this

NMPA- China Accepts NDA for BeiGene & Boehringer BioChina's Tislelizumab for the treatment of r/r cHL

Shots:
  •  Boehringer Ingelheim (BI) and BeiGene are in collaboration since 2013 for the development of tislelizumab
  • BI BioXcellence is providing CMC services and also helping BeiGene with process & analytical method- supply of GMP clinical material- and CMC filing support with the NMPA
  • Boehringer claims to provide manufacturing support to BeiGene for tislelizumab for global market- if approved in china
Click here / | Ref: Boehringer Ingelheim | Image:  PR news wire
Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions